Business
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025Secured new $10.0 million debt facility at a lower interest rate to replace remaining outstanding $7.85 million debt balance with Avenue Capital Cash, cash equivalents and marketable securities of $12.2 million as of December 31, 2024, includes $7.3 million in gro
About this update from Clene Inc.
[{"type":"image","alt":"Clene Inc.","displaySize":"","headline":null,"caption":"Clene Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dqllcqG43QFquU0vfLNVhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188","width":300,"height":72}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured new $10.0 million debt facility at a lower interest rate to replace remaining outstanding $7.85 million debt balance with Avenue Capital ","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $12.2 million as of December 31, 2024, includes $7.3 million in gross proceeds raised on October 1, 2024","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene collecting and analyzing biomarker NfL data from its large NIH-sponsored Early Access Protocol (EAP), for evaluation in the third quarter to satisfy the U.S. Food and Drug Administration (FDA) recommendation for additional neurofilament light chain (NfL) data","length":265,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":801,"olType":false},{"type":"text","content":"SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS.","length":502,"tagName":"p"},{"type":"text","content":"“We expect further regulatory guidance in 2025 on the critical next steps require...